期刊文献+

Her-2与ALDH1在乳腺癌中表达与相关性研究 被引量:12

Studies of correlation between Her-2 and ALDH1 expression in breast cancer
下载PDF
导出
摘要 目的:探讨乳腺癌组织中Her-2及ALDH1的表达相关性及其临床意义。方法:选取105例原发性乳腺癌标本。采用免疫组化法检测Her-2、ALDH1蛋白的表达,并结合临床病理特征进行相关性分析和无病生存期分析。结果:(1)Her-2与ALDH1在乳腺癌中的表达率分别为29.52%、66.67%。(2)乳腺癌原发灶中Her-2蛋白的表达与肿瘤大小、ER呈正相关(P≤0.05),与年龄、民族、组织学分期及病理类型、PR均无相关性(P>0.05)。ALDH1蛋白表达与年龄、民族、组织学分期及病理类型、肿瘤大小、淋巴结转移、ER、PR均未发现有相关性(P>0.05)。(3)Her-2与ALDH1在乳腺癌表达中呈正相关(r=0.192,P≤0.05)。(4)Her-2高表达患者2年无病生存率显著低于Her-2阴性患者(P<0.05),ALDH1阳性患者与阴性患者2年无病生存期无明显差异(P>0.05)。(5)COX回归模型分析结果显示Her-2是影响患者预后的独立因素(P=0.008)。Her-2的相对危险度=6.284>1。结论:ALDH1与Her-2在乳腺癌组织中的表达呈正相关。Her-2表达与乳腺癌术后患者预后呈负相关,而ALDH1表达与乳腺癌术后患者的预后无明显相关性。 Objective The aim of this study was to analyze the relationship and clinical significance of Her-2 ALDH1 in breast cancer.Methods We selected cancer tissue specimens from 105 of patients with breast cancer used in this study.Her-2,ALDH1 protein expressions were detected by immunohistochemistry and performed statistical analysis.Results(1)Her-2 and ALDH1 positivity in breast cancer was 29.52%,66.67% respectively.(2)HER2 expression was positively correlated with the tumor size and ER expression(P≤0.05),no correlation with age,nationality,histologic stages and pathological types(P≤0.05).this study did not found a correlation between ALDH1 and age,nationality,histologic stages,pathological types,tumor size,lymph node metastasis,ER or PR(P0.05).(3)Expression of Her-2 and ALDH1 in breast cancer was positively correlated.(4)2-year disease-free survival rate in Her-2 positive patients was significantly lower than the Her-2 negative patients.no significant statistical difference observed in 2-year disease-free survival rate from ALDH1 positive or negative breast cancer patients(P0.05).(5)Results of the analysis of COX regression model revealed Her-2 as a independent factor to indicate the poor prognosis in patients with breast cancer(P=0.008,RR=6.284).Conclusion The expression of Her-2 and ALDH1 was significantly correlated in patients with Her-2 positive breast cancer.
出处 《现代仪器》 CAS 2012年第6期26-29,33,共5页 Modern Instruments
基金 国家自然科学基金(项目编号:81160275) 中华医学会临床医学科研专项资金-柯莱逊肿瘤生物治疗研究专项资金(项目编号:2011-14) 延边大学科技发展计划项目(2012)第50号
关键词 乳腺癌 乳腺癌干细胞 HER-2 ALDH1免疫组织化学 Breast cancer stem cell Her-2 ALDH1 Immunohistochemistry
  • 相关文献

参考文献9

  • 1Visvader, J.E. and G.J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008.8(10):755-68.
  • 2Kakarala, M. and M.S. Wicha, Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol, 2008.26(17):2813-20.
  • 3Welte, Y., et al., Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal, 2010. 8(1):6.
  • 4Makino, S., The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum, 1959.15(Suppl 1): p. 196-8.
  • 5Piccart-Gebhart, M.J., et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005. 353(16):1659-72.
  • 6Ginestier, C., et al., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007.1(5): 555-67.
  • 7Korkaya, H., et al., HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene, 2008.27(47): p. 6120-30.
  • 8Roesler, R., et al., HER2 as a cancer stem-cell target. Lancet Oncol, 2010. 11(3):225-6.
  • 9Magnifico, A., et al., Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res, 2009. 15(6):2010-21.

同被引文献123

  • 1周宗炎.C-erbB-2、P53、ki67、ER和PR在乳腺癌中的表达及意义[J].贵州医药,2011,35(2):118-120. 被引量:9
  • 2施纯玫,杨建伟,陈奕贵,陈帆,陈强.8例局部晚期胃癌新辅助化疗后再切除初步临床观察[J].福建医药杂志,2005,27(5):34-36. 被引量:3
  • 3黄海林,邹林颖,何远翔,王为民,王强,张军初.乳腺癌的治疗进展[J].中国医药,2006,1(5):317-319. 被引量:18
  • 4陈晓耕,林志彬.局部晚期胃癌的新辅助化疗的临床研究[J].齐齐哈尔医学院学报,2006,27(11):1297-1299. 被引量:8
  • 5Silver DP, Richardson AL, Eklund AC, et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer[J]. J Clin Oncol, 2010, 28 (7): 1145-1153.
  • 6Mo JI, Eggers PK, Raston CL, et al. Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles[J]. Anal Bioanal Chem, 2014, 27(6): 4562- 4569.
  • 7Yoneyama K, Konishi H, Yahata T, et al. A Phase II Study of Paclitaxel and Carboplatin with a Biweekly Schedule in Patients with Epithelial Ovarian Cancer: Gynecologic Cancer Network Trial [J]. J Nippon Med Sch, 2014, 81(1): 28-34.
  • 8Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective regimen as neoadjuvant chemotherapy for breast cancer[J]. Ann Oncol, 2010, 21(5): 961-967.
  • 9Von Minckwitz G, Untch M, NUesch E, et al. Impact of treatment characteristics on response of different breast cancer pheno types: pooled analysis of the German neo-adjuvant chemotherapy trials [J]. Breast Cancer Res Treat, 2011,125(1): 145-156.
  • 10Pignata S, Scambia G, Katsaros D. Carboplatin plus paelitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial [J]. Lancet Oneol, 2014, 34(5): 1470-1475.

引证文献12

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部